Register for email alerts and news feeds:
This journal | BMJ Group
rss
Annals of the Rheumatic Diseases 2008;67:577-579; doi:10.1136/ard.2007.086330
Copyright © 2008 BMJ Publishing Group Ltd & European League Against Rheumatism.

Do we need treatment with tumour necrosis factor blockers for giant cell arteritis?

Carlo Salvarani1, Nicolò Pipitone1, Luigi Boiardi1, Gene G Hunder2

1 Unit of Rheumatology, Arcispedale S. Maria Nuova, Reggio Emilia, Italy
2 Mayo Clinic College of Medicine, Rochester, Minnesota, USA

Correspondence to:
Dr Carlo Salvarani, Unit of Rheumatology, Arcispedale S. Maria Nuova, V. le Risorgimento N80, 42100 Reggio Emilia, Italy; salvarani.carlo@asmn.re.it

Accepted 28 January 2008

The first 150 words of the full text of this article appear below.

For many years glucocorticoids (GCs) have been known to effectively suppress the clinical manifestations of giant cell arteritis (GCA), and prevent its ischaemic complications. GCs are still the treatment of choice for this disease. It is recommended that GC therapy be commenced as soon as the diagnosis of GCA is established. An initial dose of 40–60 mg/daily of prednisone (or equivalent) as a single or divided dose is generally found to be adequate in the vast majority of the cases.1 2 Higher-dose pulse GC therapy has been advocated by some for patients with recent or pending visual disturbances, but an observational study and a randomised controlled trial (RCT) failed to demonstrate superiority of pulse over oral GC therapy in preventing ischaemic complications.3 4

The initial dose of GCs is usually given for 2 to 4 weeks until all reversible signs and symptoms have resolved and acute phase reactants are back to normal. . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Relevant Article

A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects
V M Martínez-Taboada, V Rodríguez-Valverde, L Carreño, J López-Longo, M Figueroa, J Belzunegui, E M Mola, and G Bonilla
Ann Rheum Dis 2008 67: 625-630. [Abstract] [Full Text] [PDF]

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

BMJ Careers - Latest Rheumatology Jobs

Rheumatology Jobs